DBV Technologies ADR (DBVT)

DBV Technologies Announces Plan to Implement ADS Ratio Change - GlobeNewswire

GlobeNewswire

DBV Technologies Announces Plan to Implement ADS Ratio Change

GlobeNewswire Inc.

European Equities Traded in the US as American Depositary Receipts Start Week Higher - MSN

MSN

DBV Technologies Announces Results of its 2024 Combined General Meeting - WICZ

WICZ

DBV Technologies Announces Results of its 2024 Combined General Meeting - GlobeNewswire

GlobeNewswire

DBV Technologies Announces Results of its 2024 Combined General Meeting

GlobeNewswire Inc.

DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com - MarketBeat

MarketBeat

DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com - Defense World

Defense World

HC Wainwright Lowers DBV Technologies (NASDAQ:DBVT) Price Target to $5.00 - Defense World

Defense World

Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Thursday - MSN

MSN

European Equities Traded in the US as American Depositary Receipts Rise Tuesday - MSN

MSN

European Equities Traded in the US as American Depositary Receipts Trend Lower Tuesday - MSN

MSN

DBV Technologies to Participate in Upcoming Investor Conferences - GlobeNewswire

GlobeNewswire

Participation de DBV Technologies aux conférences investisseurs en mai

GlobeNewswire Inc.

European Equities Traded in the US as American Depositary Receipts Rebound After Slow Start Tuesday - MSN

MSN

H.C. Wainwright slashes DBV Technologies shares target ahead of crucial Viaskin trial - Investing.com South Africa

Investing.com South Africa

DBV Technologies (NASDAQ:DBVT) PT Lowered to $5.00 - MarketBeat

MarketBeat

DBV Technologies earnings missed by $0.05, revenue fell short of estimates - Investing.com South Africa

Investing.com South Africa

H.C. Wainwright slashes DBV Technologies shares target ahead of crucial Viaskin trial - Investing.com

Investing.com

DBV Technologies (NASDAQ:DBVT) PT Lowered to $5.00 - MarketBeat

MarketBeat

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update - GlobeNewswire

GlobeNewswire

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

GlobeNewswire Inc.

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update - GlobeNewswire

GlobeNewswire

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN

MSN

DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com - MarketBeat

MarketBeat

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN

MSN

Assemblée Générale Mixte du 16 mai 2024

GlobeNewswire Inc.

Combined General Meeting of May 16, 2024 - Yahoo Finance

Yahoo Finance

Eosinophilic Esophagitis Pipeline, Clinical Trials, FDA Approvals, and Companies 2024 (Updated) - openPR

openPR

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024

GlobeNewswire Inc.

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

GlobeNewswire Inc.

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

GlobeNewswire Inc.

DBV Technologies Reports Full Year 2023 Financial Results and Business Update - Yahoo Finance

Yahoo Finance

DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

GlobeNewswire Inc.

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

GlobeNewswire Inc.

DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying

Benzinga

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

GlobeNewswire Inc.

Roche and Novartis’ Xolair set for FDA priority review in food allergies - Pharmaceutical Technology

Pharmaceutical Technology

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2023

GlobeNewswire Inc.

Down -25.23% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

Zacks Investment Research

DBV to start supplemental safety trial for peanut allergy patch in Q1 2024 - Clinical Trials Arena

Clinical Trials Arena

Peanut skin patch shows promise in toddlers with allergies - CBS Boston

CBS Boston

Toddlers saw peanut allergies ease after wearing 'peanut patch' in trial - NBC News

NBC News

DBV sets course on regulatory journey for peanut allergy patch - Pharmaceutical Technology

Pharmaceutical Technology

DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in ... - GlobeNewswire

GlobeNewswire

This Immunotherapy Could Be The First to Treat Milk Allergy in Children - Labiotech.eu

Labiotech.eu

DBV Battles Aimmune for Share of Peanut Allergy Treatment Market - Labiotech.eu

Labiotech.eu

DBV Technologies leaps on FDA Viaskin Peanut update news - The Pharma Letter

The Pharma Letter

DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years - GlobeNewswire

GlobeNewswire

Nuts! DBV to peel adhesive (red) tape from allergy bid; stock plunges - BioWorld Online

BioWorld Online